Author:
Balasubramanian Arul,Ibrahim Thasin,Ramalingam Kothai
Abstract
Abstract
There has to be a breakthrough in tuberculosis (TB) treatment to address issues with drug resistance, patient noncompliance, and dosage frequency. We produced durable therapeutic nanocarriers (NCs) and tested their efficiency in-vitro in macrophages infected with Mycobacterium tuberculosis. Our goal was to decrease adverse effects linked to systemic drug distribution and improve drug concentration at the target site. There are multiple pathways by which antiviral medications induce renal failure. Several novel drugs have been shown to cause direct renal tubular toxicity through their distinct impacts on kidney epithelial cells. In this present study the in-silico docking studies were performed and the silver nanoparticles of the antiviral drug Entecavir was prepared and characterized by using SEM and HR-TEM studies. The prepared nanoparticles were evaluated for its anti-tubercular activity by in-vitro and the results showed the repurposed antiviral drug showed remarkable anti-tubercular activity. There is mounting evidence that the repurposed antitubercular drug Entecavir is a viable new option for treating tuberculosis.